NS Pharma Archives -

Just days after dosing its first patient in a Duchenne muscular dystrophy trial, US biotech PepGen has pushed

Sarepta DMD rival PepGen files $115m IPO

https://pharmaphorum.com/news/sarepta-dmd-rival-pepgen-files-115m-ipo/

The FDA has approved a new therapy for the rare muscle wasting disease Duchenne muscular dystrophy (DMD) as

NS Pharma takes on Sarepta as FDA approves DMD drug

https://pharmaphorum.com/news/ns-pharma-sarepta-fda-approves-dmd-drug/

Japan’s Nippon Shinyaku Pharma has filed for approval of its Duchenne muscular dystrophy (DMD) in the US, increasing

NS Pharma steals a march on Sarepta with DMD drug

https://pharmaphorum.com/news/ns-pharma-steals-a-march-on-sarepta-with-dmd-drug/

NS Pharma